Search

Your search keyword '"Wysham, Carol H"' showing total 149 results
Start Over Author "Wysham, Carol H"
149 results on '"Wysham, Carol H"'

4. Diabetes Performance Measures: Current Status and Future Directions

Author

O'Connor, Patrick J, Bodkin, Noni L, Fradkin, Judith, Glasgow, Russell E, Greenfield, Sheldon, Gregg, Edward, Kerr, Eve A, Pawlson, L Gregory, Selby, Joseph V, Sutherland, John E, Taylor, Michael L, and Wysham, Carol H

Subjects
Biomedical and Clinical Sciences, Health Sciences, Blood Pressure, Diabetes Mellitus, Diabetes Mellitus, Type 2, Electronic Health Records, Feedback, Glycated Hemoglobin, Humans, Patient Satisfaction, Quality Assurance, Health Care, Quality Indicators, Health Care, Quality of Life, Medical and Health Sciences, Endocrinology & Metabolism, Biomedical and clinical sciences, Health sciences
Published
2011

6. Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes

Author

Miller, Eden M. and Wysham, Carol H.

Subjects
Canagliflozin -- Dosage and administration -- Complications and side effects, Empagliflozin -- Dosage and administration -- Complications and side effects, Cardiovascular diseases -- Risk factors -- Research, Health
Abstract

CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES * Provide an overview of the rationale and role of SGLT-2 inhibitor therapy * Describe the results of cardiovascular outcome trials with canagliflozin and empagliflozin [...]

Published
2018

14. Consensus report: diabetes performance measures: current status and future directions

Author

O'Connor, Patrick J., Bodkin, Noni L., Fradkin, Judith, Glasgow, Russell E., Greenfield, Sheldon, Gregg, Edward, Kerr, Eve A., Pawlson, L. Gregory, Selby, Joseph V., Sutherland, John E., Taylor, Michael L., and Wysham, Carol H.

Subjects
United States. Centers for Disease Control and Prevention -- Reports, United States. Veterans Health Administration -- Reports, Cholesterol -- Measurement -- Reports, Diabetes therapy -- Quality management -- Measurement -- Reports, Patient compliance -- Measurement -- Reports, Diabetes -- Care and treatment -- Measurement -- Reports, Practice guidelines (Medicine) -- Measurement -- Reports, Medical records -- Measurement -- Reports, Health, American Diabetes Association -- Reports
Abstract

OVERVIEW: Just as treatment guidelines for diabetes care were at the forefront of medical guideline development, (1) diabetes has been a prominent focus of performance measurement and quality improvement initiatives [...]

Published
2011
Full Text
View/download PDF

15. SGLT-2 inhibition in the kidney: changing paradigms in the treatment of type 2 diabetes mellitus

Author

Miller, Eden M., Nicholas, Susanne B., and Wysham, Carol H.

Subjects
Diabetes therapy -- Methods, Kidneys -- Health aspects, Type 2 diabetes -- Drug therapy, Health
Abstract

INTRODUCTION The pathophysiology of type 2 diabetes mellitus T2DM) is recognized as a complex interplay of several defects. Of these, insulin resistance in muscle and liver and impaired insulin secretion [...]

Published
2014

16. 100-OR: ADA Presidents’ Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1)

Author

ROSENSTOCK, JULIO, primary, WYSHAM, CAROL H., additional, FRIAS, JUAN P., additional, KANEKO, SHIZUKA, additional, LEE, CLARE, additional, LANDO, LAURA FERNANDEZ, additional, MAO, HUZHANG, additional, CUI, XUEWEI, additional, and THIEU, VIVIAN, additional

Published
2021
Full Text
View/download PDF

23. New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

Author

Wysham, Carol H.

Subjects
Type 2 diabetes -- Care and treatment, Type 2 diabetes -- Patient outcomes, Type 2 diabetes -- Research, Cardiovascular diseases -- Risk factors, Cardiovascular diseases -- Research, Obesity -- Care and treatment, Obesity -- Research, Patient compliance -- Research, Health
Published
2010

24. Update on insulin management in type 2 diabetes

Author

Neumiller, Joshua J., Odegard, Peggy Soule, and Wysham, Carol H.

Subjects
Eli Lilly and Co. -- Management, Insulin resistance -- Care and treatment, Pancreatic beta cells, Insulin, Type 2 diabetes -- Care and treatment, Diabetics -- Care and treatment, Weight loss -- Care and treatment, Pharmaceutical industry, Company business management, Health
Abstract

Type 2 diabetes is a progressive disease characterized by insulin resistance and progressive β-cell dysfunction. (1) With the prevalence of type 2 diabetes increasing and with people being diagnosed at [...]

Published
2009

28. Evidence supports prediabetes treatment

Author

Neumiller, Joshua J., primary, Kalyani, Rita R., additional, Herman, William H., additional, Grant, Richard W., additional, Wysham, Carol H., additional, Inzucchi, Silvio E., additional, Hirsch, Irl B., additional, Fonseca, Vivian A., additional, Buse, John B., additional, and Barrett, Eugene J., additional

Published
2019
Full Text
View/download PDF

31. Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study.

Author

Wysham, Carol H., Gauthier-Loiselle, Marjolaine, Bailey, Robert A., Manceur, Ameur M., Lefebvre, Patrick, Greenberg, Morris, Duh, Mei Sheng, and Young, James B.

Subjects
*DIABETIC nephropathies, *TYPE 2 diabetes, *INSURANCE claims, *CHRONIC kidney failure, *ELECTRONIC health records, *COMPARATIVE studies, *HEALTH insurance, *RESEARCH methodology, *MEDICAL cooperation, *RESEARCH, *EVALUATION research, *RETROSPECTIVE studies, *DISEASE complications
Abstract

Objective: To develop and validate models allowing the prediction of major adverse chronic renal outcomes (MACRO) in patients with type 2 diabetes mellitus (T2DM) using insurance claims data.Methods: The Optum Integrated Real World Evidence Electronic Health Records and Claims de-identified database (10/01/2006-09/30/2016) was used to identify T2DM patients ≥50 years old. Risk factors were assessed over a 12-month baseline period, and MACRO were subsequently assessed until the end of data availability, continuous enrollment, or death. Separate models were built for moderate-to-severe diabetic kidney disease (DKD), end-stage renal disease (ESRD), and renal death. A random split-sample approach was employed, where 70% of the sample served for model development (training set) and the remaining 30% served for validation (testing set). C-statistics were used to assess model performance.Results: A total of 160,031 patients were included. Risk factors associated with MACRO for all models included adapted diabetes complications severity index, heart failure, anemia, diabetic nephropathy, and CKD. C-statistics ranged between 0.70 (moderate-to-severe DKD) and 0.84 (renal death) in the testing set. A substantial proportion (e.g. 88.7% for moderate-to-severe DKD) of patients predicted to be at high-risk of MACRO did not have diabetic nephropathy, proteinuria, or CKD at baseline.Conclusions: The models developed using insurance claims data could reliably predict the risk of MACRO in patients with T2DM and enabled patients at higher-risk of DKD to be identified in the absence of baseline diabetic nephropathy, CKD, or proteinuria. These models could help establish strategies to reduce the risk of MACRO in T2DM patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials

Author

DeVries, J. Hans, primary, Bailey, Timothy S., additional, Bhargava, Anuj, additional, Gerety, Gregg, additional, Gumprecht, Janusz, additional, Heller, Simon, additional, Lane, Wendy, additional, Wysham, Carol H., additional, Zinman, Bernard, additional, Bak, Britta A., additional, Hachmann-Nielsen, Elise, additional, and Philis-Tsimikas, Athena, additional

Published
2018
Full Text
View/download PDF

41. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION1 andEDITION2 subgroup analysis)

Author

Roussel, Ronan, primary, d'Emden, Michael C., additional, Fisher, Miles, additional, Ampudia‐Blasco, F. Javier, additional, Stella, Peter, additional, Bizet, Florence, additional, Cali, Anna M. G., additional, and Wysham, Carol H., additional

Published
2017
Full Text
View/download PDF

45. Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

Author

DeVries, J. Hans, Bailey, Timothy S., Bhargava, Anuj, Gerety, Gregg, Gumprecht, Janusz, Heller, Simon, Lane, Wendy, Wysham, Carol H., Zinman, Bernard, Bak, Britta A., Hachmann‐Nielsen, Elise, and Philis‐Tsimikas, Athena

Subjects
BLOOD sugar, HYPOGLYCEMIA, TREATMENT of diabetes, PEOPLE with diabetes, FASTING
Abstract

Aims: To investigate the association between day‐to‐day fasting self‐monitored blood glucose (SMBG) variability and risk of hypoglycaemia in type 1 (T1D) and type 2 diabetes (T2D), and to compare day‐to‐day fasting SMBG variability between treatments with insulin degludec (degludec) and insulin glargine 100 units/mL (glargine U100). Materials and Methods: Data were retrieved from two double‐blind, randomized, treat‐to‐target, two‐period (32 weeks each) crossover trials of degludec vs glargine U100 in T1D (SWITCH 1, n = 501) and T2D (SWITCH 2, n = 720). Available fasting SMBGs were used to determine the standard deviation (SD) of day‐to‐day fasting SMBG variability for each patient and the treatment combination. The association between day‐to‐day fasting SMBG variability and overall symptomatic, nocturnal symptomatic and severe hypoglycaemia was analysed for the pooled population using linear regression, with fasting SMBG variability included as a three‐level factor defined by population tertiles. Finally, day‐to‐day fasting SMBG variability was compared between treatments. Results: Linear regression showed that day‐to‐day fasting SMBG variability was significantly associated with overall symptomatic, nocturnal symptomatic and severe hypoglycaemia risk in T1D and T2D (P < 0.05). Day‐to‐day fasting SMBG variability was significantly associated (P < 0.01) with all categories of hypoglycaemia risk, with the exception of severe hypoglycaemia in T2D when analysed within tertiles. Degludec was associated with 4% lower day‐to‐day fasting SMBG variability than glargine U100 in T1D (P = 0.0082) and with 10% lower day‐to‐day fasting SMBG variability in T2D (P < 0.0001). Conclusions: Higher day‐to‐day fasting SMBG variability is associated with an increased risk of overall symptomatic, nocturnal symptomatic and severe hypoglycaemia. Degludec has significantly lower day‐to‐day fasting SMBG variability vs glargine U100. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

46. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes

Author

Oster, Gerry, primary, Sullivan, Sean D., additional, Dalal, Mehul R., additional, Kazemi, Mahmood R., additional, Rojeski, Maria, additional, Wysham, Carol H., additional, Sung, Jennifer, additional, Johnstone, Bryan, additional, Cali, Anna M.G., additional, Wei, L.J., additional, Traylor, Louise, additional, Anhalt, Henry, additional, Hull, Michelle, additional, Van Vleet, John, additional, and Meneghini, Luigi F., additional

Published
2016
Full Text
View/download PDF

48. What's New in the Evolving Management of Type 2 Diabetes: Individualizing Therapy with Novel Treatment Options.

Author

Wysham, Carol H.

Subjects
HYPOGLYCEMIA, TYPE 2 diabetes diagnosis, GENETICS of type 2 diabetes, TYPE 2 diabetes risk factors, TYPE 2 diabetes treatment, HEART failure risk factors, WEIGHT gain risk factors, GLUCAGON-like peptide 1, METFORMIN, MEMBRANE proteins, TYPE 2 diabetes complications, CARDIOVASCULAR diseases risk factors, DIAGNOSTIC errors, DRUG side effects, GENETIC polymorphisms, TYPE 2 diabetes, PHENOTYPES, DISEASE management, GENETIC markers, DISEASE progression, INDIVIDUALIZED medicine, THERAPEUTICS, DISEASE risk factors
Published
2018

49. Safety and Efficacy of Insulin Degludec/ Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.

Author

Wysham, Carol H., Campos, Carlos, and Kruger, Davida

Subjects
*COMBINATION drug therapy, *INSULIN, *TYPE 2 diabetes, *TREATMENT effectiveness, *GLUCAGON-like peptide-1 agonists, *PHARMACODYNAMICS
Abstract

Novel co-formulations of basal insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists have provided new options for patients with type 2 diabetes who are not reaching recommended glycemic targets. The components of currently available co-formulations (insulin degludec/ liraglutide [IDegLira,] and insulin glargine U100/lixisenatide [iGlarLixi]) act synergistically to address multiple pathophysiologic defects while minimizing the side effects associated with either component when used alone. In Europe, these products are approved for use in patients on regimens of one or more oral antidiabetic drugs; in the United States, they are indicated for use as an adjunct to diet and exercise in patients with type 2 diabetes inadequately controlled with either basal insulin or their respective GLP-1 receptor agonist component. This article reviews key clinical trials in which these products were initiated in insulin-naive patients and describes how they can be safely and effectively titrated in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results